The GLP aggregated and excerpted this blog/article to reflect the diversity of news, opinion and analysis.
The White House Office of Science & Technology Policy (OSTP) has announced a major effort to update the Coordinated Framework for the Regulation of Biotechnology. OSTP is seeking comments to inform the revisions. They especially need feedback from scientists, but comments from citizens in all walks of life are welcome.
We encourage you to provide comments to OSTP on the questions below, and we invite you to sign a letter showing your support for thoughtful regulatory change.
Because the federal comment website can be cumbersome, we will collect your comments and submit them on your behalf. The full list of questions asked by OSTP can be found in Federal Register Notice 80 FR 60414 and in Docket FDA-2015-N-3403.
Do you have examples or case studies highlighting experiences with the US biotechnology regulatory system? Have you experienced or observed any barriers to research involving biotechnology, or barriers to making products of biotechnology available to the public? How could the agencies reduce those barriers?
What would improve transparency, coordination, and efficiency of the regulatory system? How could regulatory agencies better communicate their roles and responsibilities both to scientists and to the general public?
We hope many scientists will take this opportunity to provide comments about biotechnology regulation.
The review of the Coordinated Framework provides scientists a special opportunity to speak to the White House and the regulatory agencies in the interest of enacting real change.
The first call for public comments ends on November 13, 2015 but we will continue to collect and submit your comments as the effort to update the Coordinated Framework progresses.
Read full, original post: You can improve US biotechnology regulation
